Fred Saad, MD, FRCS

Dr. Fred Saad presents a post-hoc analysis of the Phase 3 ARANOTE trial, demonstrating that darolutamide plus androgen-deprivation therapy significantly improves radiographic progression-free survival and delays metastatic castration-resistant prostate cancer in patients with metastatic hormone-sensitive prostate cancer, with consistent efficacy across disease volume subgroups and a favorable safety profile.

Fred Saad, CQ, MD, FRCS, FCAHS, discusses next steps for the investigation of darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy findings from the ARANOTE trial in patients with metastatic hormone-sensitive prostate cancer.

Fred Saad, MD, FRCS, discusses prostate-specific antigen (PSA) response and time to PSA progression with the combination of abiraterone acetate and olaparib in patients with metastatic castration-resistant prostate cancer.

Fred Saad, MD, FRCS, discusses the impact of apalutamide on nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN trial.

Fred Saad, MD, FRCS, discusses unanswered questions from the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Fred Saad, MD, FRCS, discusses unique characteristics of apalutamide compared with other antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Fred Saad, MD, FRCS, discusses the safety profile of apalutamide in nonmetastatic castration-resistant prostate cancer.

Fred Saad, MD, FRCS, discusses the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.